

9. (Previously presented) The method of claim 6, wherein the monoclonal antibody is a chimeric monoclonal antibody containing constant regions and variable regions from different species.

10. (Previously presented) The method of claim 6, wherein the monoclonal antibody is a humanized monoclonal antibody.

11. (Canceled)

12. (Currently amended) A method for preventing a T cell mediated autoimmune response associated with type I diabetes comprising administering to a subject in need of such treatment a prophylactically effective amount of an anti-gp39 antibody or a gp39-binding fragment thereof, ~~comprising variable regions~~ which antibody or fragment comprises a hypervariable region of monoclonal antibody 24-31 (ATCC Accession Number HB11712) ~~or monoclonal antibody 89-76, or of an antibody having the gp39 binding characteristics thereof.~~

13. (Currently amended) The method of claim 12, wherein the gp39 antagonist is a gp39-binding antibody fragment ~~comprising variable regions of monoclonal antibody 24-31.~~

14. (Currently amended) The method of claim 13, wherein the gp39-binding antibody fragment is a Fab or F(ab')₂ fragment ~~comprising variable regions of monoclonal antibody 24-31.~~

15. (Canceled)

16. (Canceled)

17. (Previously presented) The method of claim 9, wherein the chimeric monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 24-31.

18. (Canceled)

19. (Previously presented) The method of claim 10, wherein the humanized monoclonal anti-gp39 antibody comprises variable regions of monoclonal antibody 24-31.

20. (Canceled)

21. (Canceled)